AVELUMAB was accepted for Priority Review by FDA. The drug is sponsored by Merck KGaA, Darmstadt, Germany, which in the US and Canada operates as EMD Serono. The drug is being developed through an alliance between Merck KGaA and and Pfizer Inc. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1...
How’s this for a paradox: The better cancer centers become at keeping patients alive, the more expensive cancer care becomes. This brutal tradeoff hits harder in rural areas, where the cancer burden is higher and the investigator and clinical trial representation is lower.
